Technology Bundle ID
TAB-3558

Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers

Applications
Linked ID
E-068-2020-0
Lead Inventors
Matthew Hall (NCATS)
Co-Inventors
Jonathan Shrimp (NCATS)
Juan Marugan (NCATS)
Ke Kong (NCATS)
Min Shen (NCATS)
Mindy Davis (NCATS)
Olivia Lee (NCATS)
Samarjit Patnaik (NCATS)
Toble Lee (NCATS)
Wei Zhao (NCATS)
ICs
This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express the phase 2 detoxifying enzyme SULT1A1.
Commercial Applications
Further clinical work with the YC-1 derivates could establish these heterocyclic alcohol compounds as therapies for SULT1A1 expressing cancers.
Competitive Advantages
The identification of structurally related anti-cancer compounds is a novel treatment type for SULT1A1-expressing cancer cells. In addition, the work done to establish these compounds suggests that SULT1A1 expression may serve as a biomarker for patient selection.

Request More Info

Licensing Contact: